Half-life describes a gradual decline
During elimination, half-life is the time associated with drug levels falling by half. The remaining amount continues to decline over additional half-lives. Reaching the end of one half-life therefore does not mean that there is no medicine left.
In a simplified illustration with no further doses and the same half-life throughout, a reference amount falls to one-half, then one-quarter, then one-eighth after successive half-lives. This explains the term; it is not a way to calculate your own blood level or decide when to inject. Absorption, repeated doses, and the product’s characteristics matter in real treatment.
Semaglutide and tirzepatide have different pharmacokinetic descriptions
The Wegovy prescribing information describes semaglutide’s elimination half-life as approximately one week. The Zepbound prescribing information reports approximately five to six days for tirzepatide in the populations described in its pharmacokinetics section.
These figures describe the respective medicines; they do not make the products interchangeable. A longer half-life alone does not establish stronger weight-loss effects, fewer side effects, or a better choice for an individual. Those are different questions from how gradually a drug is eliminated.
A weekly schedule is not a seven-day expiry clock
A prescription’s dosing interval tells you when to use the medicine as directed. Its half-life describes part of what happens to the medicine afterward. Confusing the two can lead someone to assume that a dose is completely gone when the next date arrives.
For a fictional example, a patient who feels hungry near the end of a week might conclude that the previous injection has vanished. The calendar and that sensation do not establish a drug level. Our hunger-between-doses guide explains how to describe the pattern without turning it into a self-directed dose change.
Your symptoms are useful information, but they are not a drug-level test
Appetite, side effects, and treatment progress need clinical interpretation. They cannot be converted into a percentage of medication remaining. Likewise, feeling better after stopping does not prove that every effect or interaction risk has ended.
The NIDDK medication overview explains why treatment decisions take several factors into account, including health conditions, other medicines, benefits, and side effects. Report severe or persistent symptoms promptly; do not wait for a half-life calculation to tell you when to seek care.
Why the last actual dose matters when care changes
If you are considering a treatment interruption or a different provider, report what you took and when you last took it. A new appointment or shipping date does not remove the previous medicine from your body. The receiving clinician needs the medication history to decide on a suitable plan.
That is one reason CoreAge Rx’s intake review matters when someone arrives from another service. Use our provider-transition guide to organize the current prescription and recent dose history, then read the CoreAge Rx service overview for context. Its doctor-messaging guidance describes how to raise clinical questions through the member portal.
CoreAge Rx offers compounded semaglutide and tirzepatide. Compounded products are not FDA-approved, and label information for an approved product does not establish the quality or suitability of another preparation. FDA explains the concerns with unapproved GLP-1 products. Discuss approved options and your individual treatment needs with the prescriber.
Common questions
Does one half-life mean the medicine is completely out of my body?
No. It describes a reduction by half during elimination, followed by further gradual decline. It does not define a universal point when every clinical effect or risk ends.
Can half-life tell me when to restart after a break?
Not on its own. Restarting depends on the specific product, time off treatment, previous regimen, symptoms, and clinical assessment. Follow the instructions from your prescriber.
Are all GLP-1 medicines in the body for the same length of time?
No. Medicines and formulations differ. Use information for the actual product being discussed rather than treating the GLP-1 category as one interchangeable medication.
Sources and fact-checking
Sources checked 2026-09-09. CoreAge Rx pages support descriptions of its service; medical and regulatory sources support the educational context. Offers and availability can change.